News | March 20, 2009

U.S. Honor Roll Hospitals Choose ZOLL’s LifeVest

March 19, 2009 - The ZOLL Medical Corp. LifeVest Wearable Defibrillator has been prescribed for patients by physicians at all of the “Honor Roll” hospitals designated by U.S. News and World Report.
Patients at increased risk for sudden cardiac arrest (SCA) who wear the LifeVest allow their physicians time to decide how best to manage them long-term. The LifeVest reportedly has a 98 percent first shock success rate for treating patients with SCA, with no bystander intervention required.
The LifeVest features a unique, noninvasive technology that continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device alerts the patient —who may still be conscious—prior to delivering a shock. The device releases a conductive gel onto the therapy electrodes to protect the skin, and then delivers a shock to restore normal heart rhythm. The entire event usually occurs in less than a minute.
The LifeVest may be prescribed for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk. It may also be prescribed for patients whose comorbidities, including infections caused by placement of ICDs, prevent them undergoing immediate implant surgery for an ICD.

The 19 “Honor Roll” hospitals include such esteemed medical facilities as Johns Hopkins in Baltimore; the Mayo Clinic in Rochester, MN.; Ronald Reagan UCLA Medical Center in Los Angeles; Cleveland Clinic in Ohio; Massachusetts General Hospital in Boston; New York Presbyterian University Hospitals of Columbia and Cornell in New York; University of California, San Francisco Medical Center; Brigham and Women’s Hospital in Boston; Duke University Medical Center, Durham, NC.; Hospital of the University of Pennsylvania, Philadelphia; University of Washington Medical Center in Seattle; Barnes-Jewish Hospital/Washington University, St. Louis; University of Michigan Hospitals and Health Centers, Ann Arbor; University of Pittsburgh Medical Center; Vanderbilt University Medical Center, Nashville; Stanford Hospitals and Clinics, Stanford, CA.; University of Chicago Medical Center; Cedars-Sinai Medical Center, Los Angeles; and Yale-New Haven Hospital, New Haven, CT.
For more information, visit www.zoll.com

Related Content

wearable defibrillators prevent sudden cardiac death in pediatric patients
Feature | Sudden Cardiac Arrest| May 11, 2017
May 11, 2017 — A new study shows that the use of a wearable cardioverter defibrillator (WCD) is safe and effective in
Physio-Control Launches HeartSine samaritan PAD 360P Automated External Defibrillator in United States
Technology | Defibrillator Monitors| April 24, 2017
Physio-Control announced April 19 that the company’s HeartSine samaritan PAD 360P (SAM 360P) fully automatic external...
AEDs, automated external defibrillators, requirements, U.S. schools, JACC study
News | Defibrillator Monitors| March 30, 2017
Automated external defibrillators (AEDs) are associated with increased survival of sudden cardiac arrest when installed...
Philips, FDA, class I recall, HeartStart MRx Monitor/Defibrillator
News | Defibrillator Monitors| March 28, 2017
Philips and the U.S. Food and Drug Administration (FDA) announced the company has initiated a recall of its HeartStart...
Zoll, Hospital Wearable Defibrillator, HWD, FDA premarket approval
Technology | Defibrillator Monitors| March 10, 2017
Zoll Medical Corp. announced that the company’s Hospital Wearable Defibrillator (HWD) has been granted premarket...
LifePak, AED, sudden cardiac arrest, defibrillator, automatic external defibrillator

A Physio-Control LifePak CR Plus defibrillator shown in use during a hand-off to paramedics, who use larger, more sophisticated defibrillator-monitors (behind gloved paramedic).

Feature | Sudden Cardiac Arrest| September 28, 2016 | Allied Market Research
Automated external defibrillators (AED) are portable and lightweight devices used to deliver an electric shock throug
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
Cath lab, clinical trial, clinical study, defibrillator monitors
News | December 16, 2014
A faster, coordinated emergency response in collaboration with hospital cardiac catheterization laboratories in each...
3-D Printing, Congenital heart, The Children's Hospital of Philadelphia (CHOP)
News | December 01, 2014
Physician-researchers from the Cardiac Center at The Children’s Hospital of Philadelphia (CHOP) presented new findings...
Overlay Init